Majamil

Diclofenac Sodium, the active ingredient in Majamil, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for systemic use. It is employed to relieve pain and reduce inflammation in musculoskeletal conditions such as osteoarthritis and rheumatoid arthritis. GNH USA supplies Majamil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac Sodium acts on inflammatory pathways to provide analgesic and anti‑inflammatory effects in several musculoskeletal disorders.

Osteoarthritis: reduces joint pain and improves functional mobility. Rheumatoid arthritis: diminishes synovial inflammation and joint tenderness. Acute musculoskeletal pain: provides rapid pain relief after injury or strain. Post‑operative pain: helps control pain following minor surgical procedures. Dysmenorrhea: alleviates menstrual‑related cramping and discomfort.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastro‑intestinal discomfort, such as dyspepsia or abdominal pain. - Nausea or vomiting. - Headache. - Dizziness or vertigo. - Mild skin rash or itching. - Elevated liver enzymes detected in routine labs.

Serious or Rare Side Effects: - Gastro‑intestinal ulceration or bleeding, potentially life‑threatening. - Severe hepatic injury or hepatitis. - Acute renal failure or worsening of chronic kidney disease. - Cardiovascular events such as myocardial infarction or stroke. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylactic or severe hypersensitivity reactions.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

Assess gastrointestinal risk: consider gastro‑protective agents in patients with prior ulcer disease. Monitor renal function: check serum creatinine and electrolytes, especially in the elderly or dehydrated. Use lowest effective dose: limit duration to the shortest period necessary for symptom control. Avoid in known hypersensitivity: discontinue if rash, angioedema, or anaphylaxis occurs. Caution with anticoagulants: increased bleeding risk when combined with warfarin or similar agents. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Diclofenac Sodium may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened risk of serious bleeding. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Lithium: increased lithium serum concentrations leading to toxicity. - Methotrexate: reduced renal clearance, raising methotrexate levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: risk of electrolyte imbalance and renal impairment. - Corticosteroids: synergistic increase in gastrointestinal ulcer risk. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding tendency.